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SUPPLEMENTARY TABLES 
Supplementary Table 1 
Table 1: IS/LV% values  
IS/LV% from histological staining compared to LGE and ASL (2SD threshold). The number of histological slices used for analysis matches the 
spatial extent of each CMR method 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Histology (7 
slices) T2-mapping 
Histology (6 
slices) ASL perfusion mapping T1-mapping 
Control 64.3 ± 6.1 60.3 ± 5.8 (p = 0.43) 64.3 ± 9.6 65.9 ± 5.6 (p = 0.71) 59.3 ± 9.2 (p = 0.40) 
IPC 59.8 ± 7.9 50.7 ± 5.4 (p = 0.02) 59.8 ± 7.9 53.9 ± 14.3 (p = 0.33) 47.3 ± 13.8 (p = 0.04) 
Vehicle 65.4 ± 7.0 65.4 ± 10.1 (p = 0.32) 61.4 ± 7.0 57.9 ± 5.0 (p = 0.79) 58.3 ± 13.8 (p = 0.90) 
CsA 58.0 ± 12.6 62.8 ± 13.1 (p = 0.32) 57.3 ± 12.1 61.5 ± 12.6 (p = 0.10) 47.2 ± 16.6 (p = 0.12) 
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Supplementary Table 2 
Table 2: AAR/LV% values  
AAR/LV% from histological staining compared to T2 mapping, ASL (1SD threshold) and T1-mapping. The number of histological slices used for 
analysis matches the spatial extent of each CMR methods. 
 
  
Histology  
(7 slices) LGE  
Histology  
(6 slices) ASL perfusion mapping 
Control 32.3 ± 3.7 31.7 ± 5.8 (p = 0.74) 31.5 ± 4.8 24.8 ± 11.2 (p = 0.28) 
IPC 16.8 ± 3.0 17.8 ± 4.9 (p = 0.77)  15.6 ± 3.3 26.6 ± 17.9 (p = 0.45) 
Vehicle 34.9 ± 9.6 29.2 ± 5.8 (p = 0.07)  29.0 ± 8.3 25.1 ± 11.8 (p = 0.14)  
CsA 21.9 ± 4.5 19.2 ± 6.9 (p = 0.44)  20.0 ± 4.7 23.6 ± 20.3 (p = 0.69)  
 
 
 
 
 
 
 
 
 
 
 
  
Histology  
(7 slices) T2 -mapping 
Histology  
(6 slices) ASL perfusion mapping T1 -mapping 
Control 64.3 ± 6.1 60.3 ± 5.8 (p = 0.43) 64.3 ± 9.6 65.9 ± 5.6 (p = 0.71) 59.3 ± 9.2 (p = 0.40) 
IPC 59.8 ± 7.9 50.7 ± 5.4 (p = 0.02) 59.8 ± 7.9 53.9 ± 14.3 (p = 0.33) 47.3 ± 13.8 (p = 0.04) 
Vehicle 65.4 ± 7.0 65.4 ± 10.1 (p = 0.32) 61.4 ± 7.0 57.9 ± 5.0 (p = 0.79) 58.3 ± 13.8 (p = 0.90) 
CsA 58.0 ± 12.6 62.8 ± 13.1 (p = 0.32) 57.3 ± 12.1 61.5 ± 12.6 (p = 0.10) 47.2 ± 16.6 (p = 0.12) 
4 
 
 
Supplementary Table 3 
Table 3: Quantitative values from T2 mapping, perfusion mapping and T1 mapping 
Quantitative normal and elevated or reduced values for T2 mapping, perfusion mapping (1SD and 2SD thresholds) and T1 mapping. p values 
from one-way ANOVA with Bonferroni correction are given to compare Control vs. IPC groups and Vehicle vs. CsA groups. 
  
  T2 [ms] Perfusion (1std threshold) [ml/g/min] 
  Normal Elevated Normal (1std)  Reduced (1std)  
Control 17.8 ± 2.3   21.5 ± 3.0   14.0 ± 3.4   4.3 ± 1.0   
IPC 19.6 ± 3.4 (p > 0.9999) 26.8 ± 5.4 (p = 0.07)  21.0 ± 5.0 (p = 0.47) 5.4 ± 2.8 (p > 0.9999) 
Vehicle 17.3 ± 1.9   22.7 ± 2.4   17.0 ± 0.8   1.6 ± 1.6   
CsA 17.7 ± 1.9 (p > 0.9999) 23.8 ± 2.5 (p = 0.95) 28.9 ± 11.1 (p = 0.02) 7.8 ± 4.4 (p = 0.41) 
 
 
   Perfusion (2 SD threshold) [ml/g/min] T1 [s] 
  Normal (2std) Reduced (2std)  Normal Elevated 
Control 8.2 ± 2.3   2.3 ± 0.9   1.7 ± 0.1   1.9 ± 0.1   
IPC 13.7 ± 6.1 (p = 0.47)  0.6 ± 3.6 (p > 0.9999) 1.7 ± 0.3 (p > 0.9999) 2.0 ± 0.3 (p > 0.9999) 
Vehicle 12.7 ± 1.6   1.2 ± 3.3   1.5 ± 0.5   2.0 ± 0.1   
CsA 19.8 ± 7.6 (p = 0.13)  2.3 ± 4.4 (p > 0.9999) 1.6 ± 0.4 (p > 0.9999) 2.0 ± 0.1 (p > 0.9999) 
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SUPPLEMENTARY FIGURES 
 
Supplementary Figure 1: Treatment groups for murine in vivo IRI 
Mice were randomized to control or treatment groups for each study.  
A. IPC study: control group received standard IRI protocol of 15 minutes stabilization, 30 
minutes index ischemia and 72 hours reperfusion. IPC group received 5 minutes 
stabilization, one cycle of IPC consisting of 5 minutes ischemia and 5 minutes reperfusion, 
followed by 30 minutes index ischemia and 72 hours reperfusion. 
B. CsA study: both groups received standard IRI protocol of 15 minutes stabilization, 30 
minutes index ischemia and 72 hours reperfusion. Control group received a matched volume 
dose of vehicle (cremophor / ethanol-94%). CsA group received CsA 10mg/kg. Vehicle and 
CsA were administered as single intravenous dose delivered 5 minutes prior to the onset of 
reperfusion. 
 
 
